Our commitment to bringing our patients only the highest quality products means that our purchasing department is working constantly to source the best products as they become available across the state. There are only a handful of the 60 licensed cultivations currently operating and demand for that limited amount of product is incredibly high, so stores may be delayed until enough products are readily available. We plan to open our first store in Blue Springs, MO this winter with our remaining stores in Lake Lotawana, Kearney and Excelsior Springs each opening 1-2 months afterwards.

Kansas City Cannabis Company Dispensary Locations:

• 1713 NW Burdett Crossing, Blue Springs, MO 64105
• 9322 S. 7 Highway, Lake Lotawana, MO 64064
• 310 S Platte Clay Way, Kearney, MO 64060
• 149 Crowne Hill Rd, Excelsior Springs, MO 64024

To address this accurately, we must acknowledge how and why cannabis is priced, and how local as well as regional markets and seasons cause price fluctuations.

Before getting into market demand, we must address the cost of production. Prices can vary widely depending on the cultivation methods used. For example, indoor grows tend to be much more expensive to operate than outdoor and greenhouse grows because of the amount of electricity needed. Cannabis cultivated indoors also tends to fetch a higher price than its outdoor equivalent due to the belief that indoor cultivations allow for selection of superior genetics that produce higher THC content when environmental variables are properly controlled. No matter how a producer chooses to cultivate, they must charge enough to cover the cost of production.

As a response to demand, cannabis prices tend to be higher the closer to the date recreational sales are launched. That’s because the industry in the newly legalized state is typically consists of only a handful of producers who monopolize the market until sufficient competition is established. As the industry matures and more businesses emerge and fortify, supply increases. That makes the industry more competitive, and where competition abounds, prices dip so as to attract customers who now have a variety of options to choose from. Eventually, mature state programs like those in Oregon and Washington produce more cannabis than they can sell. There aren’t enough retail stores to handle the oversupply, and cultivator’s margins are reduced to barely cover the cost of production.

Nevada and California, on the other hand, are still new entries into the recreational market. Nevada has only recently caught up to a shortage problem, and some say that California is well on its way to a shortage of its own. It may be hard to imagine that the Golden State, known for having the nation’s most abundant harvest of cannabis could possibly have an undersupply. The reason isn’t a lack of producers, it’s a lack of legal producers. There are thousands of illegal growers operating out of California—only a very small fraction of those operations have applied or received licenses. If the state enforces its regulations strictly and keeps black market weed out of the legal market there won’t be enough cannabis to supply retail stores pretty soon.

It will likely take a few years before Missouri overcomes these market adjustments to reach a point of stabilization. Prices will fluctuate with the changes in supply and demand and eventually settle into a somewhat normal range as the market matures. The likelihood of recreational legislation passing in the next few years further complicates this as pricing could change drastically with the increased sales volume that a recreational market usually brings.

Medical Marijuana (MMJ), is the use of cannabis and its active compounds such as cannabinoids, terpenes, and flavonoids, to treat a patient’s symptom or condition under the direct recommendation of a physician. People have been using cannabis as medicine for centuries and there are mountains of anecdotal evidence showing that cannabis works to relieve a number of symptoms. Unfortunately, the federal government still maintains that cannabis is a Schedule 1 drug with “no currently accepted medical use”. As a result of the restrictions it has placed upon cannabis production and research, the federal government claims that limited clinical evidence exists to examine the safety and efficacy of using cannabis to treat diseases. Truth be told, there have actually been over 20,000 studies on cannabis, making it one of the most studied plants on earth. A quick search in PubMed shows over 2,400 cannabis studies in 2019 alone. Preliminary evidence suggests that cannabis can reduce nausea and vomiting during chemotherapy, improve appetite in people with HIV/AIDS, reduces chronic pain and muscle spasms and treats severe forms of epilepsy among many other common ailments.

The first direct evidence of cannabis use by humans dates back 2,500 years from traces found in wooden artifacts buried with people who lived along China’s Silk Road. According to an encyclopedic definition found on Wikipedia, Cannabis is indigenous to Central Asia and the Indian subcontinent. Hemp is possibly one of the earliest plants to be cultivated. Cannabis has been cultivated in Japan since the pre-Neolithic period for its fibres and as a food source and possibly as a psychoactive material. An archeological site in the Oki Islands near Japan contained cannabis achenes from about 8000 BC, probably signifying use of the plant. Hemp use archaeologically dates back to the Neolithic Age in China, with hemp fiber imprints found on Yangshao culture pottery dating from the 5th millennium BC. The Chinese later used hemp to make clothes, shoes, ropes, and an early form of Cannabis was an important crop in ancient Korea, with samples of hempen fabric discovered dating back as early as 3000 BCE.